Table 3.
Predictors of locoregional recurrence (n = 385)
| Variable | Value | Univariable |
Multivariable |
||
|---|---|---|---|---|---|
| Hazard ratio (CI) | P | Hazard ratio (CI) | P | ||
| Age | Per year | 1.01 (0.99-1.04) | .252 | 1.02 (0.99-1.04) | .187 |
| Sex | Female | Reference | Reference | ||
| Male | 1.78 (1.09-2.91) | .021 | 2.08 (1.24-3.48) | .005 | |
| Performance status | 0 | Reference | Reference | ||
| 1 | 1.90 (1.14-3.19) | .014 | 1.31 (0.75-2.28) | .341 | |
| 2 | 2.09 (0.73-5.98) | .169 | 1.27 (0.40-4.00) | .680 | |
| 3 | 3.53 (0.84-14.93) | .086 | 2.78 (0.60-12.90) | .192 | |
| T stage | 1 | Reference | Reference | ||
| 2 | 1.67 (0.50-5.66) | .407 | 1.26 (0.37-4.36) | .712 | |
| 3 | 4.13 (1.23-13.79) | .021 | 2.54 (0.72-8.95) | .148 | |
| 4 | 5.17 (1.55-17.28) | .008 | 2.87 (0.81-10.17) | .102 | |
| x | 0 (0-∞) | .996 | 0 (0-∞) | .998 | |
| N stage (TNM 7) | 0 | Reference | Reference | ||
| 1 | 2.24 (1.19-4.26) | .013 | 2.23 (1.13-4.39) | .021 | |
| 2 | 1.37 (0.64-2.90) | .416 | 0.79 (0.34-1.82) | .576 | |
| 3 | 3.05 (1.63-5.73) | <.001 | 1.85 (0.91-3.75) | .088 | |
| x | 0 (0-∞) | .996 | 0 (0-∞) | .998 | |
| N stage (TNM 8) | 0 | Reference | |||
| 1a | 2.17 (1.28-3.71) | .004 | |||
| 1b | 0 (0-∞) | .997 | |||
| 1c | 2.19 (0.93-5.14) | .073 | |||
| x | 0 (0-∞) | .996 | |||
| RT completion | Completed as planned | Reference | Reference | ||
| Incomplete or interrupted∗ | 5.29 (2.83-9.90) | <.001 | 4.96 (2.40-10.27) | <.001 | |
| Chemotherapy | MMC 5FU | Reference | Reference | ||
| MMC capecitabine | 0.92 (0.56-1.51) | .747 | 0.95 (0.56-1.58) | .830 | |
| Single agent | 1.24 (0.17-9.03) | .833 | 1.91 (0.25-14.62) | .532 | |
| None | 0.71 (0.10-5.15) | .732 | 0.57 (0.07-4.57) | .597 | |
Abbreviations: 5FU = 5-fluorouracil; CI = 95% confidence interval; MMC = mitomycin-c; RT = radiation therapy.
∗
An interruption in radiation therapy was defined as any extension more than 2 days over the planned overall treatment time.